Ischemic-like condition releases norepinephrine and purines from different sources in superfused rat spleen strips.
Transmitters and cotransmitters of the sympathetic nervous system are involved in the regulation of a variety of immune cell functions. However, it is not entirely clear what stimuli lead to the release of these molecules in immune organs. In this study, we investigated whether local ischemia can cause the parallel release of norepinephrine and its cotransmitter, ATP, in the spleen. Ischemic-like conditions, simulated by transient (15 min) O(2) and glucose deprivation, elicited a reversible increase in the release of both norepinephrine and purines from superfused spleen strips preloaded with [3H]norepinephrine or [3H]adenosine. HPLC analysis of the released tritium label revealed a net increase in the amount of ATP, ADP, AMP, adenosine, inosine, hypoxanthine and xanthine in response to ischemic-like condition. Selective O(2) or glucose deprivation, and Ca(2+)-free conditions differentially affected the outflow of [3H]norepinephrine and [3H]purines, indicating that they derived from different sources. The ABC transporter inhibitors glibenclamide (100 microM) and verapamil (100 microM) as well as low-temperature inhibited [3H]purine release evoked by ischemic-like conditions. Surgical denervation of the spleen reduced endogenous catecholamine content and [3H]norepinephrine uptake of the spleen, but not that of [3H]adenosine. In summary, these results demonstrate the release of norepinephrine and purines in response to an ischemic-like condition in an immune organ. Although both could provide an important source of extracellular catecholamines and purines involved at various levels of immunomodulation, the source and mechanism of norepinephrine and purine efflux seem different.
Sperlágh
B
B
Department of Pharmacology, Institute of Experimental Medicine, Hungarian Academy of Sciences, H-1450 POB 67, Budapest, Hungary. sperlagh@koki.hu
Dóda
M
M
Baranyi
M
M
Haskó
G
G
D000225:Adenine / Q000493:pharmacokinetics; D000241:Adenosine / Q000493:pharmacokinetics*; D000244:Adenosine Diphosphate / Q000493:pharmacokinetics; D000249:Adenosine Monophosphate / Q000493:pharmacokinetics; D000255:Adenosine Triphosphate / Q000493:pharmacokinetics; D000818:Animals; D002118:Calcium / Q000494:pharmacology; D019271:Hypoxanthine / Q000493:pharmacokinetics; D007288:Inosine / Q000493:pharmacokinetics; D007511:Ischemia / Q000276:immunology* / Q000378:metabolism*; D008297:Male; D009638:Norepinephrine / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar; D013154:Spleen / Q000098:blood supply / Q000294:innervation / Q000378:metabolism*; D013562:Sympathectomy; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D013566:Sympathomimetics / Q000493:pharmacokinetics*; D013779:Tetrodotoxin / Q000494:pharmacology; D014316:Tritium; D014665:Vasodilator Agents / Q000493:pharmacokinetics*; D019820:Xanthine / Q000493:pharmacokinetics
D013566:Sympathomimetics; D014665:Vasodilator Agents; D014316:Tritium; D019820:Xanthine; D019271:Hypoxanthine; D000249:Adenosine Monophosphate; D013779:Tetrodotoxin; D007288:Inosine; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D000225:Adenine; D000241:Adenosine; D002118:Calcium; D009638:Norepinephrine